ReviewThe journal of headache and pain2009
New drugs for migraine.
Review in The journal of headache and pain, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
- Anti-migraine effect of ∆European journal of pharmacology · 2018Article
- Neurovascular contributions to migraine: Moving beyond vasodilation.Neuroscience · 2016Review
- Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.European journal of clinical pharmacology · 2016Article
- ASICs as therapeutic targets for migraine.Neuropharmacology · 2015Review
- Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan.Neuropsychiatric disease and treatment · 2014Review
- Article
- The use of antidepressants for headache prophylaxis.CNS neuroscience & therapeutics · 2011Review
- Review
- Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraine.The journal of headache and pain · 2011Article
- Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?BMC neurology · 2011Review
- Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?Internal and emergency medicine · 2011Review
- Dispute settlement understanding on the use of Botox in chronic migraine.The journal of headache and pain · 2011Article
- Chronic migraine: comorbidities, risk factors, and rehabilitation.Internal and emergency medicine · 2010Review
- Increased serum levels of brain-derived neurotropic factor during migraine attacks: a pilot study.The journal of headache and pain · 2010Article
- Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine.The journal of headache and pain · 2010Article
- Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.The journal of headache and pain · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the triptans, a calcitonin gene-related peptide blocker (telcagepant) is the first acute medicine that has been developed primarily for treatment of acute migraine. Otherwise, the new drugs have been developed first for other purposes, like anticonvulsants, antihypertensives and antidepressants used for migraine prophylaxis. For acute attacks, a new way to administer a traditional drug like dihydroergotamine is under way, and documentation of efficacy in migraine has been gained for some commonly used painkillers and anti-inflammatory drugs, and for some herbal extracts. Based on insights into the basic pathophysiological mechanisms of the disorder, some drugs have been developed which seem promising in early phase II studies (NOS inhibitors and 5HT1F-receptor agonists). In the future, development and enhancements of existing medicines must be accompanied by increased efforts to develop truly new migraine drugs based on knowledge of the pathophysiology if one wishes to reduce substantially the great burden migraine poses on patients and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.